Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

37.49
+0.73562.00%
Volume:617
Turnover:23.13K
Market Cap:17.62M
PE:- -
High:37.49
Open:37.49
Low:37.49
Close:36.75
52wk High:37.90
52wk Low:28.59
Shares:469.95K
Float Shares:469.95K
Volume Ratio:1.32
T/O Rate:0.13%
Dividend:0.41
Dividend Rate:1.09%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson (JNJ) Stock May Trade At A Discount As Europe Backs Tecvayli

Simply Wall St.
·
Yesterday

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

TIPRANKS
·
Yesterday

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

TradingKey
·
Yesterday

Novartis's Multiple Sclerosis Trial Results Match Best Hopes

Dow Jones
·
Yesterday

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Stock News
·
Yesterday

Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023

Dow Jones
·
Yesterday

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Yesterday

【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92

TradingKey
·
Yesterday

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Yesterday

Tellgen Corporation Secures Six New Medical Device Approvals

Stock News
·
Yesterday

Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Dow Jones
·
Yesterday

Medical Sector Hitting an Earnings Inflection Point? 512170 Ends Green Amid AI4S Boost for HK CXO Stocks

Deep News
·
Yesterday

NetraMark Appoints Abivax Regulatory Chief Keith Fournier to Board

Reuters
·
Yesterday

Satellos to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Dow Jones
·
Yesterday

Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib

TIPRANKS
·
Yesterday

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

TIPRANKS
·
Yesterday

Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT Newswires Live
·
Yesterday

Eli Lilly (LLY) Eyes Merida Deal As Trial Data Strengthens Autoimmune Push

Simply Wall St.
·
Yesterday